Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 516 of 6351
-
Gut bacteria may tame pancreatitis — probiotic combo put to the test
Disease control Recruiting nowBackground: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) has become the second most common cause of acute pancreatitis in China, accounting for up to 42.4% of cases, with high recurrence rates and substantial disease burden. Disease severity and recurrence risk are…
Phase 4 • Sponsor: Jianyin Zhou • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a simple device keep mosquitoes away better than spraying?
Prevention Not yet recruitingMalaria is a major problem in western Kenya, particularly around Lake Victoria. Whilst current prevention methods like bed nets and vaccines help to reduce malaria burden, additional tools are needed to better protect communities from malaria. The investigators will test a new te…
Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
New pill aims to keep AML away after transplant
Disease control Recruiting nowThis is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for bladder cancer patients: avoiding bladder removal
Disease control Recruiting nowThis is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO) followed by trimodal therapy (TMT). Enrolled patients …
Phase 2 • Sponsor: Leslie Ballas • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a cancer drug tame dangerous brain vessels?
Disease control Recruiting nowBrain arteriovenous malformations (AVMs) are responsible for hemorrhagic strokes, particularly in children and young adults. They can also be responsible for chronic neurological disorders: motor or sensory deficits, disturbances of higher functions, epilepsy or disabling headach…
Phase 2/3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could a bionic pancreas simplify diabetes care in your Doctor's office?
Disease control Recruiting nowThe goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care when ordered by primary care providers. The main qu…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New smart drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for ulcerative colitis: Long-Term remission trial begins
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 286 …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Promising drug combo aims to control advanced breast cancer when standard therapy fails
Disease control Recruiting nowThe goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped…
Phase 2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take on tough bone cancer in first human test
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of FH-FOLR1 ST chimeric antigen receptor (CAR) T cells and how well they work in treating patients with osteosarcoma that recurred or spread from where it first started to nearby tissue, lymph nodes, or distant part…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer? early trial launches
Disease control Recruiting nowThis study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stage…
Phase 1/2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma
Disease control Recruiting nowThis study is a single arm, open label, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SSc. The study was divided into dose escalation phase and dose expansion phase.
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug duo targets hard-to-treat leukemias in early trial
Disease control Recruiting nowThe purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for HER2+ breast cancer patients who stopped responding to standard therapy
Disease control Not yet recruitingThe purpose of this study is to assess the safety and efficacy of RC48 (a HER2 antibody drug conjugate with MMAE payload) in combination with gemcitabine or capecitabine (with or without trastuzumab/inetetamab), for treatment of patients with HER2-positive advanced breast cancer …
Phase 2/3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Which drug first? new study aims to improve breast cancer treatment order
Disease control Not yet recruitingCurrently, no phase III RCT has directly compared SG and T-DXd sequencing strategies, and the predictive role of biomarkers remains unclear. Additionally, there is no standard scoring system for Trop-2 expression. The ASCENT trial utilized an H-score method (H-score = 3×%IHC3+ + …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New stent could spare tiny hearts from early surgery
Disease control Recruiting nowStarlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System. The study device is a stent that is designed to maintain patency of the Ductus Arteriosus for children who need blo…
Sponsor: Starlight Cardiovascular Inc • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill aims to keep HER2 lung cancer from returning after surgery
Disease control Recruiting nowBeamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinas…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
Disease control Recruiting nowThis study aims to evaluate the effectiveness and safety of combining fruquintinib (an oral anti-angiogenesis drug) with cetuximab-beta (an anti-EGFR antibody) in patients with RAS wild-type metastatic colorectal cancer who have already failed at least two lines of standard treat…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Triple-Drug attack on Hard-to-Treat stomach cancer shows promise in early trial
Disease control Recruiting nowThe ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC